BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Eigentler TK, Hassel JC, Berking C, Aberle J, Bachmann O, Grünwald V, Kähler KC, Loquai C, Reinmuth N, Steins M, Zimmer L, Sendl A, Gutzmer R. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev 2016;45:7-18. [PMID: 26922661 DOI: 10.1016/j.ctrv.2016.02.003] [Cited by in Crossref: 225] [Cited by in F6Publishing: 187] [Article Influence: 45.0] [Reference Citation Analysis]
Number Citing Articles
1 Izzedine H, Mathian A, Champiat S, Picard C, Mateus C, Routier E, Varga A, Malka D, Leary A, Michels J, Michot JM, Marabelle A, Lambotte O, Amoura Z, Soria JC, Kaaki S, Quellard N, Goujon JM, Brocheriou I. Renal toxicities associated with pembrolizumab. Clin Kidney J. 2019;12:81-88. [PMID: 30746132 DOI: 10.1093/ckj/sfy100] [Cited by in Crossref: 57] [Cited by in F6Publishing: 38] [Article Influence: 19.0] [Reference Citation Analysis]
2 Hall KH, Liu Y, Jiang C, Harvey RD. New and Worsening Long-term Immune-Related Adverse Events with PD-1/PD-L1 Pathway Agents in Patients with Cancer. Pharmacotherapy 2020;40:133-41. [PMID: 31863604 DOI: 10.1002/phar.2354] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
3 Boike J, Dejulio T. Severe Esophagitis and Gastritis from Nivolumab Therapy. ACG Case Rep J. 2017;4:e57. [PMID: 28459081 DOI: 10.14309/crj.2017.57] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
4 Ohara N, Ohashi K, Fujisaki T, Oda C, Ikeda Y, Yoneoka Y, Hashimoto T, Hasegawa G, Suzuki K, Takada T. Isolated Adrenocorticotropin Deficiency due to Nivolumab-induced Hypophysitis in a Patient with Advanced Lung Adenocarcinoma: A Case Report and Literature Review. Intern Med 2018;57:527-35. [PMID: 29151505 DOI: 10.2169/internalmedicine.9074-17] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 5.8] [Reference Citation Analysis]
5 Shannon VR, Anderson R, Blidner A, Choi J, Cooksley T, Dougan M, Glezerman I, Ginex P, Girotra M, Gupta D, Johnson DB, Suarez-Almazor ME, Rapoport BL. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity. Support Care Cancer 2020;28:6145-57. [PMID: 32880733 DOI: 10.1007/s00520-020-05708-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
6 Liu SY, Huang WC, Yeh HI, Ko CC, Shieh HR, Hung CL, Chen TY, Chen YJ. Sequential Blockade of PD-1 and PD-L1 Causes Fulminant Cardiotoxicity-From Case Report to Mouse Model Validation. Cancers (Basel) 2019;11:E580. [PMID: 31022941 DOI: 10.3390/cancers11040580] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
7 Shulgin B, Kosinsky Y, Omelchenko A, Chu L, Mugundu G, Aksenov S, Pimentel R, DeYulia G, Kim G, Peskov K, Helmlinger G. Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis. Oncoimmunology 2020;9:1748982. [PMID: 32934874 DOI: 10.1080/2162402X.2020.1748982] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
8 Saeed M, Xu Z, De Geest BG, Xu H, Yu H. Molecular Imaging for Cancer Immunotherapy: Seeing Is Believing. Bioconjug Chem 2020;31:404-15. [PMID: 31951380 DOI: 10.1021/acs.bioconjchem.9b00851] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
9 Mortezaee K. Immune escape: A critical hallmark in solid tumors. Life Sci 2020;258:118110. [PMID: 32698074 DOI: 10.1016/j.lfs.2020.118110] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 23.0] [Reference Citation Analysis]
10 Geisler AN, Phillips GS, Barrios DM, Wu J, Leung DYM, Moy AP, Kern JA, Lacouture ME. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol 2020;83:1255-68. [PMID: 32454097 DOI: 10.1016/j.jaad.2020.03.132] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 31.0] [Reference Citation Analysis]
11 Rasmussen TA, Anderson JL, Wightman F, Lewin SR. Cancer therapies in HIV cure research. Curr Opin HIV AIDS 2017;12:96-104. [PMID: 27607592 DOI: 10.1097/COH.0000000000000328] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
12 Peng L, Mao QQ, Jiang B, Zhang J, Zhao YL, Teng XD, Yang JS, Xia Y, Chen SQ, Stebbing J, Jiang H. Bilateral Posterior Uveitis and Retinal Detachment During Immunotherapy: A Case Report and Literature Review. Front Oncol 2020;10:549168. [PMID: 33240807 DOI: 10.3389/fonc.2020.549168] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Romitan DM, Rădulescu D, Berindan-Neagoe I, Stoicescu L, Grosu A, Rădulescu L, Gulei D, Ciuleanu TE. Cardiomyopathies and Arrhythmias Induced by Cancer Therapies. Biomedicines 2020;8:E496. [PMID: 33198152 DOI: 10.3390/biomedicines8110496] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
14 Lacey J, Lomax AJ, McNeil C, Marthick M, Levy D, Kao S, Nielsen T, Dhillon HM. A supportive care intervention for people with metastatic melanoma being treated with immunotherapy: a pilot study assessing feasibility, perceived benefit, and acceptability. Support Care Cancer 2019;27:1497-507. [PMID: 30392112 DOI: 10.1007/s00520-018-4524-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 Abdelbaky SB, Ibrahim MT, Samy H, Mohamed M, Mohamed H, Mustafa M, Abdelaziz MM, Forrest ML, Khalil IA. Cancer immunotherapy from biology to nanomedicine. J Control Release 2021;336:410-32. [PMID: 34171445 DOI: 10.1016/j.jconrel.2021.06.025] [Reference Citation Analysis]
16 Troxell ML, Higgins JP, Kambham N. Antineoplastic Treatment and Renal Injury: An Update on Renal Pathology Due to Cytotoxic and Targeted Therapies. Adv Anat Pathol 2016;23:310-29. [PMID: 27403615 DOI: 10.1097/PAP.0000000000000122] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
17 Reynolds K, Thomas M, Dougan M. Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade. Oncologist 2018;23:991-7. [PMID: 29853659 DOI: 10.1634/theoncologist.2018-0174] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 15.0] [Reference Citation Analysis]
18 Daher A, Matsuoka CK, Loghin ME, Penas-prado M, Tummala S. Neuromuscular Weakness Syndromes from Immune Checkpoint Inhibitors: A Case Series and Literature Review. Journal of Immunotherapy and Precision Oncology 2019;2:93-100. [DOI: 10.4103/jipo.jipo_3_19] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
19 Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K; ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv119-iv142. [PMID: 28881921 DOI: 10.1093/annonc/mdx225] [Cited by in Crossref: 853] [Cited by in F6Publishing: 670] [Article Influence: 284.3] [Reference Citation Analysis]
20 Porcu M, De Silva P, Solinas C, Battaglia A, Schena M, Scartozzi M, Bron D, Suri JS, Willard-Gallo K, Sangiolo D, Saba L. Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features. Cancers (Basel) 2019;11:E305. [PMID: 30841554 DOI: 10.3390/cancers11030305] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 14.0] [Reference Citation Analysis]
21 Gutzmer R, Vordermark D, Hassel JC, Krex D, Wendl C, Schadendorf D, Sickmann T, Rieken S, Pukrop T, Höller C, Eigentler TK, Meier F. Melanoma brain metastases - Interdisciplinary management recommendations 2020. Cancer Treat Rev 2020;89:102083. [PMID: 32736188 DOI: 10.1016/j.ctrv.2020.102083] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
22 Cramer P, Bresalier RS. Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors. Curr Gastroenterol Rep 2017;19:3. [PMID: 28124291 DOI: 10.1007/s11894-017-0540-6] [Cited by in Crossref: 81] [Cited by in F6Publishing: 60] [Article Influence: 20.3] [Reference Citation Analysis]
23 Boyle DA. Cancer and the Broken Heart: Complications and Implications of Therapy-Related Cardiotoxicity. J Infus Nurs 2018;41:229-40. [PMID: 29958259 DOI: 10.1097/NAN.0000000000000285] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
24 El Sissy C, Marliot F, Haicheur N, Kirilovsky A, Scripcariu D, Lagorce-pagès C, Galon J, Pagès F. Mise au point sur l’Immunoscore et ses potentielles implications cliniques. Annales de Pathologie 2017;37:29-38. [DOI: 10.1016/j.annpat.2016.12.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
25 Gomes F, Serra-Bellver P, Lorigan P. The role of nivolumab in melanoma. Future Oncol 2018;14:1241-52. [PMID: 29328782 DOI: 10.2217/fon-2017-0484] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
26 Oppel-Heuchel H, Grimm MO. [Therapy monitoring and management of adverse events in PD-1/PD-L1 immune checkpoint inhibition]. Urologe A 2016;55:677-90. [PMID: 27146870 DOI: 10.1007/s00120-016-0109-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
27 Briet C, Albarel F, Kuhn E, Merlen E, Chanson P, Cortet C. Expert opinion on pituitary complications in immunotherapy. Annales d'Endocrinologie 2018;79:562-8. [DOI: 10.1016/j.ando.2018.07.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
28 Real M, Barnhill MS, Higley C, Rosenberg J, Lewis JH. Drug-Induced Liver Injury: Highlights of the Recent Literature. Drug Saf 2019;42:365-87. [PMID: 30343418 DOI: 10.1007/s40264-018-0743-2] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 36.0] [Reference Citation Analysis]
29 Spallarossa P, Sarocchi M, Tini G, Arboscello E, Toma M, Ameri P, Porto I. How to Monitor Cardiac Complications of Immune Checkpoint Inhibitor Therapy. Front Pharmacol 2020;11:972. [PMID: 32676031 DOI: 10.3389/fphar.2020.00972] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
30 Su C, Wang H, Liu Y, Guo Q, Zhang L, Li J, Zhou W, Yan Y, Zhou X, Zhang J. Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer. Front Oncol 2020;10:554313. [PMID: 33072580 DOI: 10.3389/fonc.2020.554313] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
31 Lee KA, Kim HR, Yoon SY. Rheumatic complications in cancer patients treated with immune checkpoint inhibitors. Korean J Intern Med 2019;34:1197-209. [PMID: 31014065 DOI: 10.3904/kjim.2019.060] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
32 Ziogas DC, Gogas H. Extending the conversation over the immune-related hepatotoxicity: author response to Dr. Gauci et al. J Immunother Cancer 2021;9:e002391. [PMID: 33737346 DOI: 10.1136/jitc-2021-002391] [Reference Citation Analysis]
33 Hock BD, McKenzie JL, Strother M, Goddard L, Butt L, Currie MJ. Functional effects of immune complexes formed between pembrolizumab and patient-generated anti-drug antibodies. Cancer Immunol Immunother 2020;69:2453-64. [PMID: 32556495 DOI: 10.1007/s00262-020-02636-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Glutsch V, Grän F, Weber J, Gesierich A, Goebeler M, Schilling B. Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy. J Immunother Cancer 2019;7:181. [PMID: 31300044 DOI: 10.1186/s40425-019-0655-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
35 Karamchandani DM, Chetty R. Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists' perspective. J Clin Pathol. 2018;71:665-671. [PMID: 29703758 DOI: 10.1136/jclinpath-2018-205143] [Cited by in Crossref: 62] [Cited by in F6Publishing: 43] [Article Influence: 20.7] [Reference Citation Analysis]
36 Park JJ, Arafath S, Kumar ST, Sharma R, Dixit D. Managing toxicities associated with immune checkpoint inhibitors. JAAPA 2021;34:32-9. [PMID: 34031312 DOI: 10.1097/01.JAA.0000735760.65235.3c] [Reference Citation Analysis]
37 Kähler KC, Eigentler TK, Gesierich A, Heinzerling L, Loquai C, Meier F, Meiss F, Pföhler C, Schlaak M, Terheyden P, Thoms KM, Ziemer M, Zimmer L, Gutzmer R; German Dermatologic Cooperative Oncology Group (DeCOG). Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. Cancer Immunol Immunother 2018;67:825-34. [PMID: 29487980 DOI: 10.1007/s00262-018-2134-z] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 16.7] [Reference Citation Analysis]
38 Eun Y, Kim IY, Sun JM, Lee J, Cha HS, Koh EM, Kim H, Lee J. Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab. Sci Rep 2019;9:14039. [PMID: 31575933 DOI: 10.1038/s41598-019-50574-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 16.0] [Reference Citation Analysis]
39 Bond DA, Alinari L. Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab. J Blood Med 2017;8:41-54. [PMID: 28546779 DOI: 10.2147/JBM.S117452] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Kethireddy N, Thomas S, Bindal P, Shukla P, Hegde U. Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab. J Oncol Pharm Pract 2021;27:207-11. [PMID: 32390537 DOI: 10.1177/1078155220921543] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
41 Wieder T, Eigentler T, Brenner E, Röcken M. Immune checkpoint blockade therapy. J Allergy Clin Immunol 2018;142:1403-14. [PMID: 29596939 DOI: 10.1016/j.jaci.2018.02.042] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 12.0] [Reference Citation Analysis]
42 Myers G. Immune-related adverse events of immune checkpoint inhibitors: a brief review. Curr Oncol 2018;25:342-7. [PMID: 30464684 DOI: 10.3747/co.25.4235] [Cited by in Crossref: 58] [Cited by in F6Publishing: 45] [Article Influence: 19.3] [Reference Citation Analysis]
43 Memon H, Patel BM. Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view. Life Sciences 2019;233:116713. [DOI: 10.1016/j.lfs.2019.116713] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 8.5] [Reference Citation Analysis]
44 Kottschade LA. Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors. Curr Oncol Rep 2018;20:24. [PMID: 29511902 DOI: 10.1007/s11912-018-0671-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
45 Metro G, Ricciuti B, Brambilla M, Baglivo S, Soli I, Minenza E, Leonardi GC, D'arpino A, Colabrese D, Tazza M, Zicari D, Minotti V, Chiari R. The safety of nivolumab for the treatment of advanced non-small cell lung cancer. Expert Opin Drug Saf 2017;16:101-9. [PMID: 27910704 DOI: 10.1080/14740338.2017.1267725] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
46 Deligiorgi MV, Panayiotidis MI, Trafalis DT. Endocrine adverse events related with immune checkpoint inhibitors: an update for clinicians. Immunotherapy 2020;12:481-510. [PMID: 32345074 DOI: 10.2217/imt-2019-0132] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
47 O'Reilly M, Mellotte G, Ryan B, O'Connor A. Gastrointestinal side effects of cancer treatments. Ther Adv Chronic Dis 2020;11:2040622320970354. [PMID: 33294145 DOI: 10.1177/2040622320970354] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
48 Yang T, Kong Z, Ma W. PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential. Hum Vaccin Immunother 2021;17:546-53. [PMID: 32643507 DOI: 10.1080/21645515.2020.1782692] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
49 Hassel JC, Heinzerling L, Aberle J, Bähr O, Eigentler TK, Grimm MO, Grünwald V, Leipe J, Reinmuth N, Tietze JK, Trojan J, Zimmer L, Gutzmer R. Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. Cancer Treat Rev 2017;57:36-49. [PMID: 28550712 DOI: 10.1016/j.ctrv.2017.05.003] [Cited by in Crossref: 157] [Cited by in F6Publishing: 122] [Article Influence: 39.3] [Reference Citation Analysis]
50 Cui PF, Ma JX, Wang FX, Zhang J, Tao HT, Hu Y. Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis. Ther Clin Risk Manag 2017;13:1259-71. [PMID: 29026313 DOI: 10.2147/TCRM.S143939] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
51 Robilliard B, Arnaud E, Gastaud L, Broner J. A case of pembrolizumab-induced autoimmune haemolytic anaemia with polymyalgia rheumatica. Eur J Cancer 2018;103:281-3. [PMID: 30286977 DOI: 10.1016/j.ejca.2018.07.318] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
52 Sun Y, Shao C, Li S, Xu Y, Xu K, Zhang Y, Huang H, Wang M, Xu Z. Programmed cell death 1 (PD-1)/PD-ligand 1(PD-L1) inhibitors-related pneumonitis in patients with advanced non-small cell lung cancer. Asia Pac J Clin Oncol 2020;16:299-304. [PMID: 32757454 DOI: 10.1111/ajco.13380] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
53 Shindiapina P, Alinari L. Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility. Ther Adv Hematol 2018;9:89-105. [PMID: 29623180 DOI: 10.1177/2040620718761777] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
54 Hartkopf AD, Taran FA, Wallwiener M, Walter CB, Krämer B, Grischke EM, Brucker SY. PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer. Breast Care (Basel) 2016;11:385-90. [PMID: 28228704 DOI: 10.1159/000453569] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
55 Kassi E, Angelousi A, Asonitis N, Diamantopoulos P, Anastasopoulou A, Papaxoinis G, Kokkinos M, Giovanopoulos I, Kyriakakis G, Petychaki F, Savelli A, Benopoulou O, Gogas H. Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma. Cancer Med 2019;8:6585-94. [PMID: 31518074 DOI: 10.1002/cam4.2533] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
56 Pan B, Liu L, Li W. A prognostic risk model based on immune-related genes predicts overall survival of patients with hepatocellular carcinoma. Health Sci Rep 2020;3:e202. [PMID: 33204848 DOI: 10.1002/hsr2.202] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Liu Y, Wang H, Deng J, Sun C, He Y, Zhou C. Toxicity of tumor immune checkpoint inhibitors-more attention should be paid. Transl Lung Cancer Res 2019;8:1125-33. [PMID: 32010590 DOI: 10.21037/tlcr.2019.11.26] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
58 Izzedine H, Mateus C, Boutros C, Robert C, Rouvier P, Amoura Z, Mathian A. Renal effects of immune checkpoint inhibitors. Nephrol Dial Transplant 2017;32:936-42. [PMID: 28025384 DOI: 10.1093/ndt/gfw382] [Cited by in Crossref: 12] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
59 Jiang R, Xu L, Huang Y, Fang C, Guo H, Li S, Wu J, Du Z. Anti–PD-1 Drug (Nivolumab) May Induce Acute and Life-Threatening Pancreatitis in Lung Cancer Patient: A Case Report. Pancreas 2018;47:e53-4. [DOI: 10.1097/mpa.0000000000001107] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
60 Shivaji UN, Jeffery L, Gui X, Smith SCL, Ahmad OF, Akbar A, Ghosh S, Iacucci M. Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management. Therap Adv Gastroenterol 2019;12:1756284819884196. [PMID: 31723355 DOI: 10.1177/1756284819884196] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 13.0] [Reference Citation Analysis]
61 Yasuda Y, Urata Y, Tohnai R, Ito S, Kawa Y, Kono Y, Hattori Y, Tsuda M, Sakuma T, Negoro S, Satouchi M. Immune-related Colitis Induced by the Long-term Use of Nivolumab in a Patient with Non-small Cell Lung Cancer. Intern Med 2018;57:1269-72. [PMID: 29279482 DOI: 10.2169/internalmedicine.9230-17] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 4.8] [Reference Citation Analysis]
62 Ikeuchi K, Okuma Y, Tabata T. Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report. Lung Cancer. 2016;99:148-150. [PMID: 27565931 DOI: 10.1016/j.lungcan.2016.07.001] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 8.2] [Reference Citation Analysis]
63 Kunogi Y, Tominaga K, Abe K, Kanazawa M, Tanaka T, Watanabe S, Kondo M, Kanamori A, Iijima M, Goda K, Nozawa Y, Ishida K, Irisawa A. Refractory Immune Checkpoint Inhibitor-Induced Colitis Improved by Tacrolimus: A Case Report. Healthcare (Basel) 2021;9:418. [PMID: 33916353 DOI: 10.3390/healthcare9040418] [Reference Citation Analysis]
64 Grimm M, Bex A, De Santis M, Ljungberg B, Catto JW, Rouprêt M, Hussain SA, Bellmunt J, Powles T, Wirth M, Van Poppel H. Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. European Urology 2019;76:368-80. [DOI: 10.1016/j.eururo.2019.05.041] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 10.5] [Reference Citation Analysis]
65 Liu YH, Zang XY, Wang JC, Huang SS, Xu J, Zhang P. Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy. Biomed Pharmacother 2019;120:109437. [PMID: 31590992 DOI: 10.1016/j.biopha.2019.109437] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
66 Okada N, Kawazoe H, Takechi K, Matsudate Y, Utsunomiya R, Zamami Y, Goda M, Imanishi M, Chuma M, Hidaka N, Sayama K, Kubo Y, Tanaka A, Ishizawa K. Association Between Immune-Related Adverse Events and Clinical Efficacy in Patients with Melanoma Treated With Nivolumab: A Multicenter Retrospective Study. Clin Ther 2019;41:59-67. [PMID: 30528047 DOI: 10.1016/j.clinthera.2018.11.004] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 15.0] [Reference Citation Analysis]
67 Arnouk J, Mathew D, Nulton E, Rachakonda V. A Celiac Disease Phenotype After Checkpoint Inhibitor Exposure: An Example of Immune Dysregulation After Immunotherapy. ACG Case Rep J 2019;6:e00158. [DOI: 10.14309/crj.0000000000000158] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
68 Polk A, Svane I, Andersson M, Nielsen D. Checkpoint inhibitors in breast cancer – Current status. Cancer Treatment Reviews 2018;63:122-34. [DOI: 10.1016/j.ctrv.2017.12.008] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 20.0] [Reference Citation Analysis]
69 Zhang X, Ran Y, Wang K, Zhu Y, Li J. Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis. Drug Des Devel Ther 2016;10:3153-61. [PMID: 27729774 DOI: 10.2147/DDDT.S115493] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
70 Kroschinsky F, Stölzel F, von Bonin S, Beutel G, Kochanek M, Kiehl M, Schellongowski P; Intensive Care in Hematological and Oncological Patients (iCHOP) Collaborative Group. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care 2017;21:89. [PMID: 28407743 DOI: 10.1186/s13054-017-1678-1] [Cited by in Crossref: 189] [Cited by in F6Publishing: 140] [Article Influence: 47.3] [Reference Citation Analysis]
71 Rocha M, Correia de Sousa J, Salgado M, Araújo A, Pedroto I. Management of Gastrointestinal Toxicity from Immune Checkpoint Inhibitor. GE Port J Gastroenterol 2019;26:268-74. [PMID: 31328141 DOI: 10.1159/000494569] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
72 Qu J, Wang L, Jiang M, Zhao D, Wang Y, Zhang F, Li J, Zhang X. A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies. Cancer Manag Res 2020;12:6493-509. [PMID: 32801888 DOI: 10.2147/CMAR.S257188] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
73 Ogawara D, Soda H, Ikehara S, Sumiyoshi M, Iwasaki K, Okuno D, Dohtsu Y, Taniguchi H, Harada T, Fukuda Y, Mukae H. Nivolumab infusion reaction manifesting as plantar erythema and pulmonary infiltrate in a lung cancer patient. Thorac Cancer 2017;8:706-9. [PMID: 28845909 DOI: 10.1111/1759-7714.12494] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
74 Sosa A, Lopez Cadena E, Simon Olive C, Karachaliou N, Rosell R. Clinical assessment of immune-related adverse events. Ther Adv Med Oncol 2018;10:1758835918764628. [PMID: 29623110 DOI: 10.1177/1758835918764628] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 18.3] [Reference Citation Analysis]
75 Kaunitz GJ, Loss M, Rizvi H, Ravi S, Cuda JD, Bleich KB, Esandrio J, Sander I, Le DT, Diaz LA Jr, Brahmer JR, Drake CG, Hollmann TJ, Lacouture ME, Hellmann MD, Lipson EJ, Taube JM. Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern. Am J Surg Pathol 2017;41:1381-9. [PMID: 28817405 DOI: 10.1097/PAS.0000000000000900] [Cited by in Crossref: 35] [Cited by in F6Publishing: 14] [Article Influence: 8.8] [Reference Citation Analysis]
76 Castinetti F, Albarel F, Archambeaud F, Bertherat J, Bouillet B, Buffier P, Briet C, Cariou B, Caron P, Chabre O, Chanson P, Cortet C, Do Cao C, Drui D, Haissaguerre M, Hescot S, Illouz F, Kuhn E, Lahlou N, Merlen E, Raverot V, Smati S, Verges B, Borson-Chazot F. French Endocrine Society Guidance on endocrine side effects of immunotherapy. Endocr Relat Cancer 2019;26:G1-G18. [PMID: 30400055 DOI: 10.1530/ERC-18-0320] [Cited by in Crossref: 49] [Cited by in F6Publishing: 14] [Article Influence: 49.0] [Reference Citation Analysis]
77 Zhou C, Wang J, Bu H, Wang B, Han B, Lu Y, Wang Z, Zhu B, Wang Z, Song Q, Ren S, Lin D, He Y, Hu X, Zhao H, Qin S. [Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version)]. Zhongguo Fei Ai Za Zhi 2020;23:65-76. [PMID: 32093450 DOI: 10.3779/j.issn.1009-3419.2020.02.01] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
78 Simeone E, Grimaldi AM, Festino L, Trojaniello C, Vitale MG, Vanella V, Palla M, Ascierto PA. Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management. Melanoma Manag 2019;6:MMT30. [PMID: 31871619 DOI: 10.2217/mmt-2019-0005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
79 Baraibar I, Melero I, Ponz-Sarvise M, Castanon E. Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer. Drug Saf 2019;42:281-94. [PMID: 30649742 DOI: 10.1007/s40264-018-0774-8] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 16.5] [Reference Citation Analysis]
80 Fessas P, Possamai LA, Clark J, Daniels E, Gudd C, Mullish BH, Alexander JL, Pinato DJ. Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms. Immunology 2020;159:167-77. [PMID: 31646612 DOI: 10.1111/imm.13141] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 15.5] [Reference Citation Analysis]
81 Kitano S, Shimizu T, Koyama T, Ebata T, Iwasa S, Kondo S, Shimomura A, Fujiwara Y, Yamamoto N, Paccaly A, Li S, Rietschel P, Sims T. Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies. Cancer Chemother Pharmacol 2021;87:53-64. [PMID: 33146741 DOI: 10.1007/s00280-020-04161-6] [Reference Citation Analysis]
82 El Majzoub I, Qdaisat A, Thein KZ, Win MA, Han MM, Jacobson K, Chaftari PS, Prejean M, Reyes-Gibby C, Yeung SJ. Adverse Effects of Immune Checkpoint Therapy in Cancer Patients Visiting the Emergency Department of a Comprehensive Cancer Center. Ann Emerg Med 2019;73:79-87. [PMID: 29880440 DOI: 10.1016/j.annemergmed.2018.04.019] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 12.0] [Reference Citation Analysis]
83 Mennini FS, Bini C, Marcellusi A, Del Vecchio M. Cost Estimate of Immune-Related Adverse Reactions Associated with Innovative Treatments of Metastatic Melanoma. Clin Drug Investig 2018;38:967-76. [DOI: 10.1007/s40261-018-0690-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
84 Tozuka T, Sugano T, Noro R, Takano N, Hisakane K, Takahashi S, Tanaka T, Kashiwada T, Takeuchi S, Kunugi S, Minegishi Y, Saito Y, Kubota K, Seike M, Gemma A. Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis. Oxf Med Case Reports 2018;2018:omy094. [PMID: 30364514 DOI: 10.1093/omcr/omy094] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
85 Russo L, Avesani G, Gui B, Trombadori CML, Salutari V, Perri MT, Di Paola V, Rodolfino E, Scambia G, Manfredi R. Immunotherapy-Related Imaging Findings in Patients with Gynecological Malignancies: What Radiologists Need to Know. Korean J Radiol 2021;22:1310-22. [PMID: 34047505 DOI: 10.3348/kjr.2020.1299] [Reference Citation Analysis]
86 Ruini C, Haas C, Mastnik S, Knott M, French LE, Schlaak M, Berking C. Primary Biliary Cirrhosis and Granulomatous Hepatitis After Immune Checkpoint Blockade in Patients With Metastatic Melanoma: Report of 2 Cases and Literature Discussion. J Immunother 2021;44:71-5. [PMID: 33323872 DOI: 10.1097/CJI.0000000000000354] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Kähler KC, Hassel JC, Heinzerling L, Loquai C, Thoms KM, Ugurel S, Zimmer L, Gutzmer R; committee on “Cutaneous Adverse Events“ of the German Working Group for Dermatological Oncology (Arbeitsgemeinschaft Dermatologische Onkologie, ADO). Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update. J Dtsch Dermatol Ges 2020;18:582-609. [PMID: 32489011 DOI: 10.1111/ddg.14128] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
88 Grieb BC, Goff LW, Goyal L, Denlinger CS. Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: Breakthroughs, Toxicities, and Future Frontiers. Am Soc Clin Oncol Educ Book 2019;39:248-60. [PMID: 31099615 DOI: 10.1200/EDBK_237555] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
89 Vani V, Regge D, Cappello G, Gabelloni M, Neri E. Imaging of Adverse Events Related to Checkpoint Inhibitor Therapy. Diagnostics (Basel) 2020;10:E216. [PMID: 32294888 DOI: 10.3390/diagnostics10040216] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
90 Yip RHL, Lee LH, Schaeffer DF, Horst BA, Yang HM. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma. Melanoma Res. 2018;28:645-647. [PMID: 30256271 DOI: 10.1097/cmr.0000000000000502] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
91 Ruggeri RM, Campennì A, Giuffrida G, Trimboli P, Giovanella L, Trimarchi F, Cannavò S. Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know). J Endocrinol Invest 2019;42:745-56. [PMID: 30471004 DOI: 10.1007/s40618-018-0984-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 8.7] [Reference Citation Analysis]
92 Furtado VF, Melamud K, Hassan K, Rohatgi S, Buch K. Imaging manifestations of immune-related adverse effects in checkpoint inhibitor therapies: A primer for the radiologist. Clin Imaging 2020;63:35-49. [PMID: 32120311 DOI: 10.1016/j.clinimag.2020.02.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Zheng Y, Meng X, Zweigenbaum P, Chen L, Xia J. Hybrid phenotype mining method for investigating off-target protein and underlying side effects of anti-tumor immunotherapy. BMC Med Inform Decis Mak 2020;20:133. [PMID: 32646421 DOI: 10.1186/s12911-020-1105-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
94 Vu A, Vassallo R, Ryu JH. Exacerbation of Previously Undiagnosed Bird Fancier's Lung by Pembrolizumab Therapy. Chest 2019;155:e79-82. [PMID: 30955583 DOI: 10.1016/j.chest.2018.12.002] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
95 Hirasawa Y, Yoshimura K, Matsui H, Kubota Y, Ishida H, Arai J, Sakaki M, Oguro N, Shida M, Taniguchi M, Hamada K, Ariizumi H, Ishiguro T, Ohkuma R, Sambe T, Horiike A, Imamura CK, Shiozawa E, Wada S, Tsurutani J, Iwamoto S, Uchida N, Kiuchi Y, Tate G, Kobayashi S, Tsunoda T. A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy. Medicine (Baltimore) 2021;100:e25774. [PMID: 34114983 DOI: 10.1097/MD.0000000000025774] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Aivazian K, Long GV, Sinclair EC, Kench JG, McKenzie CA. Histopathology of pembrolizumab-induced hepatitis: a case report. Pathology 2017;49:789-92. [PMID: 29079004 DOI: 10.1016/j.pathol.2017.07.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
97 Guo J, Chen T, Ma Z, Qiao C, Yuan F, Guo X, Liu J, Shen Y, Yu L, Xiang A. Oridonin inhibits 4T1 tumor growth by suppressing Treg differentiation via TGF-β receptor. Int Immunopharmacol 2020;88:106831. [PMID: 32853925 DOI: 10.1016/j.intimp.2020.106831] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
98 Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol 2020;17:474-502. [DOI: 10.1038/s41569-020-0348-1] [Cited by in Crossref: 73] [Cited by in F6Publishing: 55] [Article Influence: 73.0] [Reference Citation Analysis]
99 Foller S, Oppel-Heuchel H, Fetter I, Winkler Y, Grimm MO. [Adverse events of immune checkpoint inhibitors]. Urologe A 2017;56:486-91. [PMID: 28246759 DOI: 10.1007/s00120-017-0342-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
100 Mahmood SS, Chen CL, Shapnik N, Krishnan U, Singh HS, Makker V. Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: A case report. Gynecol Oncol Rep 2018;25:74-7. [PMID: 29922709 DOI: 10.1016/j.gore.2018.05.014] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
101 Garon-Czmil J, Petitpain N, Rouby F, Sassier M, Babai S, Yelehe-Okouma M, Weryha G, Klein M, Gillet P. Thyroiditis and immune check point inhibitors: the post-marketing experience using the French National Pharmacovigilance database. Fundam Clin Pharmacol 2019;33:241-9. [PMID: 30308083 DOI: 10.1111/fcp.12423] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
102 Coutzac C, Adam J, Soularue E, Collins M, Racine A, Mussini C, Boselli L, Kamsukom N, Mateus C, Charrier M, Cassard L, Planchard D, Ribrag V, Fizazi K, Loriot Y, Lepage P, Scoazec JY, Robert C, Carbonnel F, Chaput N. Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities. J Crohns Colitis. 2017;11:1238-1246. [PMID: 28967957 DOI: 10.1093/ecco-jcc/jjx081] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 23.0] [Reference Citation Analysis]
103 Cho M, Nonomura Y, Kaku Y, Nakabo S, Endo Y, Otsuka A, Kabashima K. Scleroderma-like syndrome associated with nivolumab treatment in malignant melanoma. J Dermatol 2019;46:e43-4. [DOI: 10.1111/1346-8138.14492] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
104 Vindum HH, Agnholt JS, Nielsen AWM, Nielsen MB, Schmidt H. Severe steroid refractory gastritis induced by Nivolumab: A case report. World J Gastroenterol 2020;26:1971-8. [PMID: 32390707 DOI: 10.3748/wjg.v26.i16.1971] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
105 Lu M, Zhang L, Li Y, Wang H, Guo X, Zhou J, Duan L, Si X, Xu Y, Zhang L. Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections. Thorac Cancer 2020;11:805-9. [PMID: 31970940 DOI: 10.1111/1759-7714.13313] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
106 Heinzerling L, Eigentler TK, Fluck M, Hassel JC, Heller-Schenck D, Leipe J, Pauschinger M, Vogel A, Zimmer L, Gutzmer R. Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open 2019;4:e000491. [PMID: 31231568 DOI: 10.1136/esmoopen-2019-000491] [Cited by in Crossref: 54] [Cited by in F6Publishing: 33] [Article Influence: 27.0] [Reference Citation Analysis]
107 Rasmussen TA, Søgaard OS. Clinical Interventions in HIV Cure Research. Adv Exp Med Biol 2018;1075:285-318. [PMID: 30030798 DOI: 10.1007/978-981-13-0484-2_12] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
108 Upadhrasta S, Elias H, Patel K, Zheng L. Managing cardiotoxicity associated with immune checkpoint inhibitors. Chronic Dis Transl Med 2019;5:6-14. [PMID: 30993259 DOI: 10.1016/j.cdtm.2019.02.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
109 Remon J, Mezquita L, Corral J, Vilariño N, Reguart N. Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients. J Thorac Dis 2018;10:S1516-33. [PMID: 29951303 DOI: 10.21037/jtd.2017.12.52] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
110 Grimm MO, Winkler Y, Fetter I, Oppel-Heuchel H. [Renaissance of immuno-oncology for urological tumors : Current status]. Urologe A 2016;55:621-6. [PMID: 27119960 DOI: 10.1007/s00120-016-0107-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
111 España S, Guasch I, Carcereny E. Immunotherapy rechallenge in patients with non-small-cell lung cancer. Pulmonology 2020;26:252-4. [PMID: 32354686 DOI: 10.1016/j.pulmoe.2020.01.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
112 Scott ES, Long GV, Guminski A, Clifton-Bligh RJ, Menzies AM, Tsang VH. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma. Eur J Endocrinol 2018;178:173-80. [PMID: 29187509 DOI: 10.1530/EJE-17-0810] [Cited by in Crossref: 60] [Cited by in F6Publishing: 25] [Article Influence: 15.0] [Reference Citation Analysis]
113 Ferrari SM, Fallahi P, Elia G, Ragusa F, Ruffilli I, Patrizio A, Galdiero MR, Baldini E, Ulisse S, Marone G, Antonelli A. Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies. Int J Mol Sci 2019;20:E2560. [PMID: 31137683 DOI: 10.3390/ijms20102560] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 16.0] [Reference Citation Analysis]
114 Schirrmacher V. Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis. Biomedicines 2020;8:E61. [PMID: 32188078 DOI: 10.3390/biomedicines8030061] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
115 Banna GL, Passiglia F, Colonese F, Canova S, Menis J, Addeo A, Russo A, Cortinovis DL. Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients' selection. Crit Rev Oncol Hematol 2018;129:27-39. [PMID: 30097235 DOI: 10.1016/j.critrevonc.2018.06.016] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
116 Barbosa NS, Wetter DA, Wieland CN, Shenoy NK, Markovic SN, Thanarajasingam U. Scleroderma Induced by Pembrolizumab: A Case Series. Mayo Clin Proc 2017;92:1158-63. [PMID: 28599746 DOI: 10.1016/j.mayocp.2017.03.016] [Cited by in Crossref: 60] [Cited by in F6Publishing: 40] [Article Influence: 15.0] [Reference Citation Analysis]
117 Pan CL, Chen FC. Patent trend and competitive analysis of cancer immunotherapy in the United States. Hum Vaccin Immunother 2017;13:2583-93. [PMID: 28881159 DOI: 10.1080/21645515.2017.1361074] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
118 Kikuchi F, Saheki T, Imachi H, Kobayashi T, Fukunaga K, Ibata T, Sato S, Ban N, Lyu J, Japar S, Murao K. Nivolumab-induced hypophysitis followed by acute-onset type 1 diabetes with renal cell carcinoma: a case report. J Med Case Rep 2021;15:214. [PMID: 33892782 DOI: 10.1186/s13256-020-02656-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
119 Appelbaum J, Wells D, Hiatt JB, Steinbach G, Stewart FM, Thomas H, Nghiem P, Kapur RP, Thompson JA, Bhatia S. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report. J Immunother Cancer 2018;6:82. [PMID: 30170630 DOI: 10.1186/s40425-018-0396-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
120 Shibata Y, Murakami S, Kato T. Overview of checkpoint inhibitor pneumonitis: incidence and associated risk factors. Expert Opin Drug Saf 2021;20:537-47. [PMID: 33650443 DOI: 10.1080/14740338.2021.1898584] [Reference Citation Analysis]
121 Lui RN, Chan SL. Management of Gastrointestinal Side Effects of Immune Checkpoint Inhibitors. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00702-3. [PMID: 34324843 DOI: 10.1016/j.cgh.2021.06.038] [Reference Citation Analysis]
122 Lee YJ, Kim HT, Won CH, Chang SE, Lee MW, Choi JH, Lee WJ. Characterization and Prognostic Significance of Cutaneous Adverse Events to Anti-Programmed Cell Death-1 Therapy. J Korean Med Sci 2019;34:e186. [PMID: 31269545 DOI: 10.3346/jkms.2019.34.e186] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
123 Amaral TMS, Hoffmann MC, Sinnberg T, Niessner H, Sülberg H, Eigentler TK, Garbe C. Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma. Eur J Cancer 2020;125:38-45. [PMID: 31838403 DOI: 10.1016/j.ejca.2019.10.027] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
124 Moldaver D, Hurry M, Evans WK, Cheema PK, Sangha R, Burkes R, Melosky B, Tran D, Boehm D, Venkatesh J, Walisser S, Orava E, Grima D. Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model. Lung Cancer 2020;139:185-94. [PMID: 31812889 DOI: 10.1016/j.lungcan.2019.10.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
125 Redelman-Sidi G, Michielin O, Cervera C, Ribi C, Aguado JM, Fernández-Ruiz M, Manuel O. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors). Clin Microbiol Infect 2018;24 Suppl 2:S95-S107. [PMID: 29427804 DOI: 10.1016/j.cmi.2018.01.030] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 15.7] [Reference Citation Analysis]
126 Suh KJ, Kim SH, Kim YJ, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Lee JS. Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody. Cancer Immunol Immunother 2018;67:459-70. [PMID: 29204702 DOI: 10.1007/s00262-017-2092-x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 15.8] [Reference Citation Analysis]
127 Heinzerling L, de Toni EN, Schett G, Hundorfean G, Zimmer L. Checkpoint Inhibitors. Dtsch Arztebl Int 2019;116:119-26. [PMID: 30940340 DOI: 10.3238/arztebl.2019.0119] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 19.0] [Reference Citation Analysis]
128 Gazzé G. Combination therapy for metastatic melanoma: a pharmacist's role, drug interactions & complementary alternative therapies. Melanoma Manag 2018;5:MMT07. [PMID: 30459938 DOI: 10.2217/mmt-2017-0026] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
129 Jardim DL, de Melo Gagliato D, Giles FJ, Kurzrock R. Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors. Clin Cancer Res 2018;24:1785-94. [PMID: 29212781 DOI: 10.1158/1078-0432.CCR-17-1970] [Cited by in Crossref: 27] [Cited by in F6Publishing: 12] [Article Influence: 6.8] [Reference Citation Analysis]
130 Hasegawa S, Ikesue H, Nakao S, Shimada K, Mukai R, Tanaka M, Matsumoto K, Inoue M, Satake R, Yoshida Y, Goto F, Hashida T, Nakamura M. Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database. Pharmacoepidemiol Drug Saf 2020;29:1279-94. [PMID: 32869941 DOI: 10.1002/pds.5108] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
131 Dine J, Gordon R, Shames Y, Kasler MK, Barton-Burke M. Immune Checkpoint Inhibitors: An Innovation in Immunotherapy for the Treatment and Management of Patients with Cancer. Asia Pac J Oncol Nurs 2017;4:127-35. [PMID: 28503645 DOI: 10.4103/apjon.apjon_4_17] [Cited by in Crossref: 83] [Cited by in F6Publishing: 67] [Article Influence: 20.8] [Reference Citation Analysis]
132 Farolfi A, Schepisi G, Conteduca V, Burgio SL, Lolli C, De Giorgi U. Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma. Expert Opin Drug Metab Toxicol 2016;12:1089-96. [PMID: 27450183 DOI: 10.1080/17425255.2016.1214713] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
133 Kamińska-Winciorek G, Cybulska-Stopa B, Lugowska I, Ziobro M, Rutkowski P. Principles of prophylactic and therapeutic management of skin toxicity during treatment with checkpoint inhibitors. Postepy Dermatol Alergol 2019;36:382-91. [PMID: 31616210 DOI: 10.5114/ada.2018.80272] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
134 Varricchi G, Galdiero MR, Marone G, Criscuolo G, Triassi M, Bonaduce D, Marone G, Tocchetti CG. Cardiotoxicity of immune checkpoint inhibitors. ESMO Open 2017;2:e000247. [PMID: 29104763 DOI: 10.1136/esmoopen-2017-000247] [Cited by in Crossref: 98] [Cited by in F6Publishing: 84] [Article Influence: 24.5] [Reference Citation Analysis]
135 Petrelli F, Ardito R, Borgonovo K, Lonati V, Cabiddu M, Ghilardi M, Barni S. Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. European Journal of Cancer 2018;103:7-16. [DOI: 10.1016/j.ejca.2018.07.129] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
136 Gutzmer R, Koop A, Meier F, Hassel JC, Terheyden P, Zimmer L, Heinzerling L, Ugurel S, Pföhler C, Gesierich A, Livingstone E, Satzger I, Kähler KC; German Dermatooncology Group (DeCOG). Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur J Cancer 2017;75:24-32. [PMID: 28214654 DOI: 10.1016/j.ejca.2016.12.038] [Cited by in Crossref: 108] [Cited by in F6Publishing: 87] [Article Influence: 27.0] [Reference Citation Analysis]
137 Zhou C, Wang J, Wang B, Cheng Y, Wang Z, Han B, Lu Y, Wu G, Zhang L, Song Y, Zhu B, Hu Y, Wang Z, Song Q, Ren S, He Y, Hu X, Zhang J, Yao Y, Zhao H, Wang Z, Chu Q, Duan J, Liu J, Qin S. [Chinese Experts Consensus on Immune Checkpoint Inhibitors 
for Non-small Cell Lung Cancer (2020 Version)]. Zhongguo Fei Ai Za Zhi 2021;24:217-35. [PMID: 33896153 DOI: 10.3779/j.issn.1009-3419.2021.101.13] [Reference Citation Analysis]
138 Wei W, Luo Z. Risk of gastrointestinal toxicities with PD-1 inhibitors in cancer patients: A meta-analysis of randomized clinical trials. Medicine (Baltimore). 2017;96:e8931. [PMID: 29310385 DOI: 10.1097/md.0000000000008931] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
139 Long B, Brém E, Koyfman A. Oncologic Emergencies: Immune-Based Cancer Therapies and Complications. West J Emerg Med 2020;21:566-80. [PMID: 32421502 DOI: 10.5811/westjem.2020.1.45898] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
140 Chiloiro S, Capoluongo ED, Tartaglione T, Giampietro A, Bianchi A, Giustina A, Pontecorvi A, De Marinis L. The Changing Clinical Spectrum of Hypophysitis. Trends Endocrinol Metab 2019;30:590-602. [PMID: 31345630 DOI: 10.1016/j.tem.2019.06.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
141 Warner BM, Baer AN, Lipson EJ, Allen C, Hinrichs C, Rajan A, Pelayo E, Beach M, Gulley JL, Madan RA, Feliciano J, Grisius M, Long L, Powers A, Kleiner DE, Cappelli L, Alevizos I. Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy. Oncologist 2019;24:1259-69. [PMID: 30996010 DOI: 10.1634/theoncologist.2018-0823] [Cited by in Crossref: 52] [Cited by in F6Publishing: 34] [Article Influence: 26.0] [Reference Citation Analysis]
142 Zhu L, Wang Z, Stebbing J, Wang Z, Peng L. Immunotherapy-Related Cystitis: Case Report and Review of the Literature. Onco Targets Ther 2021;14:4321-8. [PMID: 34366676 DOI: 10.2147/OTT.S321965] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
143 Heppt MV, Amaral T, Kähler KC, Heinzerling L, Hassel JC, Meissner M, Kreuzberg N, Loquai C, Reinhardt L, Utikal J, Dabrowski E, Gesierich A, Pföhler C, Terheyden P, Thoms KM, Zimmer L, Eigentler TK, Kirchberger MC, Stege HM, Meier F, Schlaak M, Berking C. Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study. J Immunother Cancer 2019;7:299. [PMID: 31722735 DOI: 10.1186/s40425-019-0800-0] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 17.0] [Reference Citation Analysis]
144 Roberts K, Culleton V, Lwin Z, O'byrne K, Hughes BG. Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities: Immune checkpoint inhibitor toxicity management. Asia-Pac J Clin Oncol 2017;13:277-88. [DOI: 10.1111/ajco.12698] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
145 Sardaro A, Ferrari C, Carbonara R, Altini C, Lavelli V, Rubini G. Synergism Between Immunotherapy and Radiotherapy in Esophageal Cancer: An Overview of Current Knowledge and Future Perspectives. Cancer Biother Radiopharm 2021;36:123-32. [PMID: 32551915 DOI: 10.1089/cbr.2020.3643] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
146 Bai X, Lin X, Zheng K, Chen X, Wu X, Huang Y, Zhuang Y. Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase. Endocrine 2020;69:670-81. [PMID: 32507965 DOI: 10.1007/s12020-020-02355-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
147 Konala VM, Adapa S, Aronow WS. Immune Checkpoint Inhibitors-Related Cardiotoxicity. Am J Ther 2020;27:e591-8. [PMID: 31008763 DOI: 10.1097/MJT.0000000000000988] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
148 Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, Stang A, Roesch A, Ugurel S. Melanoma. Lancet. 2018;392:971-984. [PMID: 30238891 DOI: 10.1016/s0140-6736(18)31559-9] [Cited by in Crossref: 346] [Cited by in F6Publishing: 169] [Article Influence: 115.3] [Reference Citation Analysis]
149 Plachouri K, Vryzaki E, Georgiou S. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview. CDS 2019;14:14-20. [DOI: 10.2174/1574886313666180730114309] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
150 Kostine M, Chiche L, Lazaro E, Halfon P, Charpin C, Arniaud D, Retornaz F, Blanco P, Jourde-Chiche N, Richez C, Stavris C. Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge. Rev Med Interne 2017;38:513-25. [PMID: 28214182 DOI: 10.1016/j.revmed.2017.01.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
151 Bisschop C, Wind TT, Blank CU, Koornstra RH, Kapiteijn E, Van den Eertwegh AJ, De Groot JWB, Jalving M, Hospers GA. Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma: Results From the Dutch Expanded Access Program. Journal of Immunotherapy 2019;42:208-14. [DOI: 10.1097/cji.0000000000000271] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
152 Liu Y, Wu W. Cardiovascular immune-related adverse events: Evaluation, diagnosis and management. Asia Pac J Clin Oncol 2020;16:232-40. [PMID: 32129935 DOI: 10.1111/ajco.13326] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
153 Phillips GS, Wu J, Hellmann MD, Postow MA, Rizvi NA, Freites-Martinez A, Chan D, Dusza S, Motzer RJ, Rosenberg JE, Callahan MK, Chapman PB, Geskin L, Lopez AT, Reed VA, Fabbrocini G, Annunziata MC, Kukoyi O, Pabani A, Yang CH, Chung WH, Markova A, Lacouture ME. Treatment Outcomes of Immune-Related Cutaneous Adverse Events. J Clin Oncol 2019;37:2746-58. [PMID: 31216228 DOI: 10.1200/JCO.18.02141] [Cited by in Crossref: 59] [Cited by in F6Publishing: 25] [Article Influence: 29.5] [Reference Citation Analysis]
154 Gerussi A, Natalini A, Antonangeli F, Mancuso C, Agostinetto E, Barisani D, Di Rosa F, Andrade R, Invernizzi P. Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models. Int J Mol Sci 2021;22:4557. [PMID: 33925355 DOI: 10.3390/ijms22094557] [Reference Citation Analysis]
155 Mazarico I, Capel I, Giménez-Palop O, Albert L, Berges I, Luchtenberg F, García Y, Fernández-Morales LA, De Pedro VJ, Caixàs A, Rigla M. Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors. J Endocrinol Invest 2019;42:1443-50. [PMID: 31093955 DOI: 10.1007/s40618-019-01058-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 8.5] [Reference Citation Analysis]
156 Yamauchi R, Araki T, Mitsuyama K, Tokito T, Ishii H, Yoshioka S, Kuwaki K, Mori A, Yoshimura T, Tsuruta O, Torimura T. The characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature review. BMC Gastroenterol. 2018;18:135. [PMID: 30170560 DOI: 10.1186/s12876-018-0864-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
157 Gao B, Lin N, Wang S, Wang Y. Minimal change disease associated with anti-PD1 immunotherapy: a case report. BMC Nephrol 2018;19:156. [PMID: 29970032 DOI: 10.1186/s12882-018-0958-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
158 Haikal A, Borba E, Khaja T, Doolittle G, Schmidt P. Nivolumab-induced new-onset seronegative rheumatoid arthritis in a patient with advanced metastatic melanoma: A case report and literature review. Avicenna J Med 2018;8:34-6. [PMID: 29404271 DOI: 10.4103/ajm.AJM_127_17] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 13.0] [Reference Citation Analysis]
159 Shingarev R, Glezerman IG. Kidney Complications of Immune Checkpoint Inhibitors: A Review. Am J Kidney Dis 2019;74:529-37. [PMID: 31303350 DOI: 10.1053/j.ajkd.2019.03.433] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 14.5] [Reference Citation Analysis]
160 Suteau V, Collin A, Menei P, Rodien P, Rousselet MC, Briet C. Expression of programmed death-ligand 1 (PD-L1) in human pituitary neuroendocrine tumor. Cancer Immunol Immunother 2020;69:2053-61. [PMID: 32445029 DOI: 10.1007/s00262-020-02611-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
161 Tada K, Kurihara Y, Myojo T, Kojima F, Ishikawa Y, Yoshiyasu N, Morimoto M, Ito R, Koyamada R, Yamashita T, Bando T, Mori S, Heike Y. Case report of nivolumab-related pneumonitis. Immunotherapy 2017;9:313-8. [DOI: 10.2217/imt-2016-0129] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
162 Acero Brand FZ, Suter N, Adam JP, Faulques B, Maietta A, Soulières D, Blais N. Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab. J Immunother Cancer. 2018;6:22. [PMID: 29548299 DOI: 10.1186/s40425-018-0332-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
163 Mataraza JM, Gotwals P. Recent advances in immuno-oncology and its application to urological cancers. BJU Int 2016;118:506-14. [PMID: 27123757 DOI: 10.1111/bju.13518] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
164 Lheureux S, Denoyelle C, Ohashi PS, De Bono JS, Mottaghy FM. Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician. Eur J Nucl Med Mol Imaging 2017;44:41-54. [PMID: 28396911 DOI: 10.1007/s00259-017-3695-3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 7.5] [Reference Citation Analysis]
165 Zheng K, Qiu W, Wang H, Si X, Zhang X, Zhang L, Li X. Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor-induced renal immune-related adverse events. Thorac Cancer 2020;11:1746-51. [PMID: 32232975 DOI: 10.1111/1759-7714.13405] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
166 Cugnet Anceau C, Abeillon J, Maillet D, Borson-chazot F, Disse E. Les dysthyroïdies sous immunothérapie anti-cancéreuse. Bulletin du Cancer 2020;107:262-71. [DOI: 10.1016/j.bulcan.2019.10.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
167 Vivar KL, Deschaine M, Messina J, Divine JM, Rabionet A, Patel N, Harrington MA, Seminario-Vidal L. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. J Cutan Pathol 2017;44:381-4. [PMID: 28000240 DOI: 10.1111/cup.12876] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 14.5] [Reference Citation Analysis]
168 Cheng MW, Hisaw LD, Bernet L. Generalized morphea in the setting of pembrolizumab. Int J Dermatol 2018;58:736-8. [DOI: 10.1111/ijd.14097] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
169 Medina P, Jeffers KD, Trinh VA, Harvey RD. The Role of Pharmacists in Managing Adverse Events Related to Immune Checkpoint Inhibitor Therapy. J Pharm Pract 2020;33:338-49. [PMID: 31694455 DOI: 10.1177/0897190019885230] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
170 Ahmed M. Checkpoint inhibitors: What gastroenterologists need to know. World J Gastroenterol 2018;24:5433-8. [PMID: 30622372 DOI: 10.3748/wjg.v24.i48.5433] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
171 Romanski NA, Holmstroem RB, Ellebaek E, Svane IM. Characterization of risk factors and efficacy of medical management of immune-related hepatotoxicity in real-world patients with metastatic melanoma treated with immune checkpoint inhibitors. Eur J Cancer 2020;130:211-8. [PMID: 32229418 DOI: 10.1016/j.ejca.2020.02.041] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
172 Simmons D, Lang E. The Most Recent Oncologic Emergency: What Emergency Physicians Need to Know About the Potential Complications of Immune Checkpoint Inhibitors. Cureus 2017;9:e1774. [PMID: 29250474 DOI: 10.7759/cureus.1774] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
173 Luu Q, Major G. Unleashing the tiger - iatrogenic autoimmunity from cancer immunotherapy drugs. JRSM Open 2018;9:2054270417746905. [PMID: 29344404 DOI: 10.1177/2054270417746905] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
174 Donaldson M, Owen JL, Chae YK, Choi JN. Management of Persistent Pruritus and Lichenoid Reaction Secondary to Nivolumab With Narrowband Ultraviolet B Phototherapy. Front Oncol 2018;8:405. [PMID: 30319970 DOI: 10.3389/fonc.2018.00405] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
175 Jennings JJ, Mandaliya R, Nakshabandi A, Lewis JH. Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies. Expert Opin Drug Metab Toxicol. 2019;15:231-244. [PMID: 30677306 DOI: 10.1080/17425255.2019.1574744] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 16.5] [Reference Citation Analysis]
176 Nishikawa M, Goshima A, Owaki H, Fuji T. Nivolumab-Induced Recurrence of Rheumatoid Arthritis in a Patient with Metastatic Gastric Adenocarcinoma. Clin Drug Investig 2019;39:1251-4. [DOI: 10.1007/s40261-019-00846-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
177 Sehgal V, Childress R. Urgent Need to Define Pretreatment Predictors of Immune Check Point Inhibitors Related Endocrinopathies: A Case Report and Review of Literature. J Transl Int Med. 2017;5:235-239. [PMID: 29340281 DOI: 10.1515/jtim-2017-0039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
178 Rapoport BL, Cooksley T, Johnson DB, Anderson R. Supportive care for new cancer therapies. Curr Opin Oncol 2021;33:287-94. [PMID: 33756517 DOI: 10.1097/CCO.0000000000000736] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
179 Zhao Q, Liu C, Liu H, Chen J. Advances in immune neoadjuvant/adjuvant therapy-related adverse events of non-small cell lung cancer. Asia Pac J Clin Oncol 2020. [PMID: 32573077 DOI: 10.1111/ajco.13378] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
180 Satzger I, Ivanyi P, Länger F, Kreipe H, Schaper-gerhardt K, Beutel G, Cornberg M, Gutzmer R. Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumab. European Journal of Cancer 2018;93:150-3. [DOI: 10.1016/j.ejca.2018.01.063] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 7.7] [Reference Citation Analysis]
181 Waidmann O, Trojan J. Immunvermittelte Nebenwirkungen unter Checkpointinhibitoren. Gastroenterologe 2017;12:490-5. [DOI: 10.1007/s11377-017-0205-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
182 Hryniewicki AT, Wang C, Shatsky RA, Coyne CJ. Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians. J Emerg Med 2018;55:489-502. [PMID: 30120013 DOI: 10.1016/j.jemermed.2018.07.005] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 12.0] [Reference Citation Analysis]
183 Okoye IS, Houghton M, Tyrrell L, Barakat K, Elahi S. Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer. Front Immunol. 2017;8:1215. [PMID: 29033936 DOI: 10.3389/fimmu.2017.01215] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 10.5] [Reference Citation Analysis]
184 Park H, Hatabu H, Ricciuti B, Aijazi SJ, Awad MM, Nishino M. Immune-related adverse events on body CT in patients with small-cell lung cancer treated with immune-checkpoint inhibitors. Eur J Radiol 2020;132:109275. [PMID: 32949913 DOI: 10.1016/j.ejrad.2020.109275] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
185 Núñez Abad M, Saval Victoria A, Franco La Rosa M, Berrocal A. Infusion reaction to nivolumab in a metastatic melanoma patient. Safe switch to another anti-programmed death-1: a case report. Melanoma Res 2021;31:88-91. [PMID: 33234847 DOI: 10.1097/CMR.0000000000000710] [Reference Citation Analysis]
186 Wang PF, Chen Y, Song SY, Wang TJ, Ji WJ, Li SW, Liu N, Yan CX. Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. Front Pharmacol. 2017;8:730. [PMID: 29093678 DOI: 10.3389/fphar.2017.00730] [Cited by in Crossref: 174] [Cited by in F6Publishing: 144] [Article Influence: 43.5] [Reference Citation Analysis]
187 Hamdeh S, Micic D, Hanauer S. Drug-Induced Colitis. Clinical Gastroenterology and Hepatology 2021;19:1759-79. [DOI: 10.1016/j.cgh.2020.04.069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]